Grodanz Elizabeth
Elizabeth Grodanz, MSN, BSN, RN Staff Nurse, Cardiac Surgery Department, Operating Room, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
J Cardiovasc Nurs. 2015 Jul-Aug;30(4):325-31. doi: 10.1097/JCN.0000000000000157.
Mitral valve repair is the standard therapy for patients with severe mitral regurgitation. Currently, robotic mitral valve repair is the least invasive surgical approach and an alternative to the traditional sternotomy. Recent studies and newer guidelines on mitral valve repair advocate for earlier referral to surgery, resulting in better long-term outcomes of valve function and decreased left ventricular remodeling.
Robotic mitral valve repair outcomes were compared with nonrobotic mitral repair outcomes through analysis of 4 recent studies, one of which was the Food and Drug Administration trial that granted approval of robotic cardiac surgery. Two studies included their own nonrobotic groups for comparison, with one comparing the robotic approach with complete sternotomy, partial sternotomy, and mini-anterolateral thoracotomy to assess all currently available techniques.
All 4 studies showed positive outcomes including decreased need for postoperative mechanical ventilation, intensive care unit length of stay, and hospital length of stay. The studies also showed that postrepair mitral regurgitation was equivalent to that of traditional open repairs at multiple different periods after surgery.
Patients should be given the option for minimally invasive robotic mitral valve repair if they have no other risk factors such as peripheral vascular disease that prevent femoral cannulation for cardiopulmonary bypass or the need for concomitant cardiac surgery such as coronary artery bypass. With the equality of robotic outcomes compared with full sternotomy valve surgery comes the need for more research into what kind of complex valve repairs can be done, which methods of repair work best with robotic techniques, whether the learning curve for robotic surgery can be shortened with more widespread use, and what outcomes can be improved upon from this standpoint. Healthcare professionals need to be aware of all choices for patients who need surgical intervention for their mitral regurgitation.
二尖瓣修复术是重度二尖瓣反流患者的标准治疗方法。目前,机器人二尖瓣修复术是侵入性最小的手术方式,是传统胸骨切开术的替代方法。近期关于二尖瓣修复术的研究和新指南主张更早转诊进行手术,从而改善瓣膜功能的长期预后并减少左心室重塑。
通过对4项近期研究的分析,比较机器人二尖瓣修复术与非机器人二尖瓣修复术的结果,其中一项是美国食品药品监督管理局批准机器人心脏手术的试验。两项研究纳入了各自的非机器人组进行比较,其中一项将机器人手术方法与完全胸骨切开术、部分胸骨切开术和迷你前外侧开胸术进行比较,以评估所有当前可用的技术。
所有4项研究均显示出积极的结果,包括术后机械通气需求减少、重症监护病房住院时间和住院时间缩短。这些研究还表明,修复后二尖瓣反流在术后多个不同时期与传统开放修复相当。
如果患者没有其他风险因素,如妨碍股动静脉插管进行体外循环的外周血管疾病或需要同期进行心脏手术(如冠状动脉搭桥术),应给予患者选择微创机器人二尖瓣修复术的机会。鉴于机器人手术结果与全胸骨切开瓣膜手术相当,需要更多研究来确定可以进行何种复杂的瓣膜修复、哪种修复方法最适合机器人技术、随着机器人手术更广泛的应用能否缩短学习曲线,以及从这个角度可以改善哪些结果。医疗保健专业人员需要了解二尖瓣反流需要手术干预的患者的所有选择。